- Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
- Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
- Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
- Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023
- Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024
More ▼
Key statistics
On Tuesday, Organon & Co (OGN:NYQ) closed at 18.52, -25.29% below its 52-week high of 24.79, set on May 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 17.96 |
---|---|
High | 18.54 |
Low | 17.82 |
Bid | 18.25 |
Offer | 18.72 |
Previous close | 18.00 |
Average volume | 2.56m |
---|---|
Shares outstanding | 255.64m |
Free float | 255.27m |
P/E (TTM) | 4.51 |
Market cap | 4.60bn USD |
EPS (TTM) | 3.99 USD |
Annual div (ADY) | 1.12 USD |
---|---|
Annual div yield (ADY) | 6.22% |
Div ex-date | Feb 23 2024 |
Div pay-date | Mar 14 2024 |
Data delayed at least 15 minutes, as of Apr 24 2024 00:00 BST.
More ▼